volum
number
decemb
natur
medicin
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
mer
cov
underscor
threat
crossspeci
transmiss
event
lead
outbreak
human
examin
diseas
potenti
sarslik
viru
current
circul
chines
horsesho
bat
popul
use
sarscov
revers
genet
system
gener
character
chimer
viru
express
spike
bat
coronaviru
mouseadapt
sarscov
backbon
result
indic
group
virus
encod
spike
wildtyp
backbon
effici
use
multipl
ortholog
sar
receptor
human
angiotensin
convert
enzym
ii
replic
effici
primari
human
airway
cell
achiev
vitro
titer
equival
epidem
strain
sarscov
addit
vivo
experi
demonstr
replic
chimer
viru
mous
lung
notabl
pathogenesi
evalu
avail
sarsbas
immunetherapeut
prophylact
modal
reveal
poor
efficaci
monoclon
antibodi
vaccin
approach
fail
neutral
protect
infect
cov
use
novel
spike
protein
basi
find
synthet
rederiv
infecti
fulllength
recombin
viru
demonstr
robust
viral
replic
vitro
vivo
work
suggest
potenti
risk
sarscov
reemerg
virus
current
circul
bat
popul
emerg
sarscov
herald
new
era
crossspeci
transmiss
sever
respiratori
ill
global
lead
rapid
spread
around
world
massiv
econom
impact
sinc
sever
strainsinclud
influenza
strain
merscovhav
emerg
anim
popul
caus
consider
diseas
mortal
econom
hardship
afflict
region
although
public
health
measur
abl
stop
sarscov
outbreak
recent
metagenom
studi
identifi
sequenc
close
relat
sarslik
virus
circul
chines
bat
popul
may
pose
futur
threat
howev
sequenc
data
alon
provid
minim
insight
identifi
prepar
futur
prepandem
virus
therefor
examin
emerg
potenti
potenti
infect
human
circul
bat
cov
built
chimer
viru
encod
novel
zoonot
cov
spike
proteinfrom
sequenc
isol
chines
horsesho
bat
context
sarscov
mouseadapt
backbon
hybrid
viru
allow
us
evalu
abil
novel
spike
protein
caus
diseas
independ
necessari
adapt
mutat
natur
backbon
use
approach
character
cov
infect
mediat
spike
protein
primari
human
airway
cell
vivo
test
efficaci
avail
immun
therapeut
togeth
strategi
translat
metagenom
data
help
predict
prepar
futur
emerg
virus
sequenc
relat
show
cov
closest
rel
epidem
sarscov
strain
fig
b
howev
import
differ
residu
bind
human
receptor
sarscov
includ
five
critic
host
rang
ref
three
residu
vari
epidem
sarscov
urbani
strain
expect
alter
bind
supplementari
fig
b
supplementari
tabl
fact
confirm
pseudotyp
experi
measur
abil
lentivirus
encod
spike
protein
enter
cell
express
human
supplementari
fig
vitro
replic
assay
ref
contrast
residu
differ
sarscov
includ
five
residu
critic
host
rang
supplementari
fig
supplementari
tabl
chang
coupl
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
mer
cov
underscor
threat
crossspeci
transmiss
event
lead
outbreak
human
examin
diseas
potenti
sarslik
viru
current
circul
chines
horsesho
bat
popul
use
sarscov
revers
genet
system
gener
character
chimer
viru
express
spike
bat
coronaviru
mouseadapt
sarscov
backbon
result
indic
group
virus
encod
spike
wildtyp
backbon
effici
use
multipl
ortholog
sar
receptor
human
angiotensin
convert
enzym
ii
replic
effici
primari
human
airway
cell
achiev
vitro
titer
equival
epidem
strain
sarscov
addit
vivo
experi
demonstr
replic
chimer
viru
mous
lung
notabl
pathogenesi
evalu
avail
sarsbas
immunetherapeut
prophylact
modal
reveal
poor
efficaci
monoclon
antibodi
vaccin
approach
fail
neutral
protect
infect
cov
use
novel
spike
protein
basi
find
synthet
rederiv
infecti
fulllength
recombin
viru
demonstr
robust
viral
replic
vitro
vivo
work
suggest
potenti
risk
sarscov
reemerg
virus
current
circul
bat
popul
emerg
sarscov
herald
new
era
crossspeci
transmiss
sever
respiratori
ill
global
lead
rapid
spread
around
world
massiv
econom
impact
sinc
sever
strainsinclud
influenza
strain
merscovhav
emerg
anim
popul
caus
consider
diseas
mortal
econom
hardship
afflict
region
although
public
health
measur
abl
stop
sarscov
outbreak
recent
metagenom
studi
identifi
sequenc
close
relat
sarslik
virus
circul
chines
bat
popul
may
pose
futur
threat
howev
sequenc
data
alon
provid
minim
insight
identifi
prepar
futur
prepandem
virus
therefor
examin
emerg
potenti
potenti
infect
human
circul
bat
cov
built
chimer
viru
encod
novel
zoonot
cov
spike
proteinfrom
sequenc
isol
chines
horsesho
bat
context
sarscov
mouseadapt
backbon
hybrid
viru
allow
us
evalu
abil
novel
spike
protein
caus
diseas
independ
necessari
adapt
mutat
natur
backbon
use
approach
character
cov
infect
mediat
spike
protein
primari
human
airway
cell
vivo
test
efficaci
avail
immun
therapeut
togeth
strategi
translat
metagenom
data
help
predict
prepar
futur
emerg
virus
sequenc
relat
show
cov
closest
rel
epidem
sarscov
strain
fig
b
howev
import
differ
residu
bind
human
receptor
sarscov
includ
five
critic
host
rang
ref
three
residu
vari
epidem
sarscov
urbani
strain
expect
alter
bind
supplementari
fig
b
supplementari
tabl
fact
confirm
pseudotyp
experi
measur
abil
lentivirus
encod
spike
protein
enter
cell
express
human
supplementari
fig
vitro
replic
assay
ref
contrast
residu
differ
sarscov
includ
five
residu
critic
host
rang
supplementari
fig
supplementari
tabl
chang
coupl
sarslik
cluster
circul
bat
coronavirus
show
potenti
human
emerg
failur
pseudotyp
lentivirus
express
spike
enter
cell
supplementari
fig
suggest
spike
unabl
bind
human
howev
similar
chang
relat
sarscov
strain
report
allow
bind
suggest
addit
function
test
requir
verif
therefor
synthes
spike
context
replicationcompet
mouseadapt
sarscov
backbon
hereaft
refer
chimer
cov
maxim
opportun
pathogenesi
vaccin
studi
mice
supplementari
fig
despit
predict
structurebas
model
pseudotyp
experi
viabl
replic
high
titer
vero
cell
supplementari
fig
similarli
sar
also
requir
function
molecul
entri
could
use
human
civet
bat
ortholog
supplementari
fig
test
abil
spike
mediat
infect
human
airway
examin
sensit
human
epitheli
airway
cell
line
ref
infect
found
robust
replic
compar
sarscov
urbani
fig
extend
find
primari
human
airway
epitheli
hae
cultur
infect
show
robust
replic
virus
fig
togeth
data
confirm
abil
virus
spike
infect
human
airway
cell
underscor
potenti
threat
crossspeci
transmiss
evalu
role
spike
mediat
infect
vivo
infect
balbc
mice
plaqueform
unit
pfu
either
fig
anim
infect
experienc
rapid
weight
loss
lethal
post
infect
dpi
contrast
infect
produc
substanti
weight
loss
lethal
mice
fig
examin
viral
replic
reveal
nearli
equival
viral
titer
lung
mice
infect
fig
wherea
lung
mice
show
robust
stain
termin
bronchiol
lung
parenchyma
dpi
fig
mice
show
reduc
airway
antigen
stain
fig
contrast
deficit
antigen
stain
observ
parenchyma
overal
histolog
score
suggest
differenti
infect
lung
tissu
supplementari
tabl
next
analyz
infect
suscept
age
anim
anim
rapidli
lost
weight
succumb
infect
supplementari
fig
b
infect
induc
robust
sustain
weight
loss
minim
lethal
trend
histolog
antigen
stain
pattern
observ
young
mice
conserv
older
anim
supplementari
tabl
exclud
possibl
mediat
infect
altern
receptor
basi
experi
use
mice
show
weight
loss
antigen
stain
infect
supplementari
fig
b
supplementari
tabl
togeth
data
indic
virus
spike
capabl
induc
weight
loss
mice
context
virul
cov
backbon
given
preclin
efficaci
ebola
monoclon
antibodi
therapi
zmapp
next
sought
determin
efficaci
sarscov
monoclon
antibodi
infect
npg
l
e
e
r
volum
number
decemb
natur
medicin
four
broadli
neutral
human
monoclon
antibodi
target
sarscov
spike
protein
previous
report
probabl
reagent
immunotherapi
examin
effect
antibodi
viral
replic
express
percentag
inhibit
viral
replic
found
wherea
wildtyp
sarscov
urbani
strongli
neutral
four
antibodi
rel
low
antibodi
concentr
fig
neutral
vari
antibodi
gener
phage
display
escap
mutant
achiev
background
level
inhibit
replic
fig
similarli
antibodi
deriv
memori
b
cell
sarscovinfect
patient
also
fail
block
replic
fig
c
three
antibodi
differ
sar
spike
amino
acid
sequenc
correspond
direct
adjac
residu
chang
found
sarscov
escap
mutant
probabl
explain
absenc
antibodi
neutral
activ
final
monoclon
antibodi
abl
achiev
neutral
high
concentr
fig
togeth
result
demonstr
broadli
neutral
antibodi
sarscov
may
margin
efficaci
emerg
sarslik
cov
strain
evalu
efficaci
exist
vaccin
infect
vaccin
age
mice
doubleinactiv
whole
sarscov
div
previou
work
show
div
could
neutral
protect
young
mice
challeng
homolog
viru
howev
vaccin
fail
protect
age
anim
augment
immun
patholog
also
observ
indic
possibl
anim
harm
vaccin
found
div
provid
protect
challeng
regard
weight
loss
viral
titer
supplementari
fig
b
consist
previou
report
heterolog
group
cov
serum
divvaccin
age
mice
also
fail
neutral
supplementari
fig
notabl
div
vaccin
result
robust
immun
patholog
supplementari
tabl
eosinophilia
supplementari
fig
togeth
result
confirm
div
vaccin
would
protect
infect
could
possibl
augment
diseas
age
vaccin
group
contrast
vaccin
mice
div
use
live
attenu
vaccin
show
potenti
crossprotect
challeng
sarscov
result
import
caveat
infect
young
mice
pfu
observ
challeng
mice
day
supplementari
fig
prior
infect
mice
high
dose
confer
protect
challeng
lethal
dose
although
minim
sarscov
neutral
respons
antisera
elicit
infect
supplementari
fig
absenc
secondari
antigen
boost
dpi
repres
expect
peak
antibodi
titer
impli
diminish
protect
sarscov
time
similar
result
show
protect
challeng
lethal
dose
sarscov
observ
age
balbc
mice
respect
weight
loss
viral
replic
supplementari
fig
howev
infect
dose
pfu
induc
weight
loss
lethal
age
anim
fig
supplementari
fig
found
vaccin
lower
dose
pfu
induc
weight
loss
also
fail
protect
age
anim
lethal
dose
challeng
supplementari
fig
f
togeth
data
suggest
challeng
may
confer
crossprotect
sarscov
conserv
epitop
requir
dose
induc
pathogenesi
preclud
use
attenu
vaccin
establish
spike
abil
mediat
infect
human
cell
caus
diseas
mice
next
synthes
fulllength
infecti
clone
base
approach
use
sarscov
fig
replic
vero
cell
reveal
deficit
rel
sarscov
fig
howev
significantli
p
attenu
primari
hae
cultur
h
infect
fig
vivo
infect
mice
demonstr
signific
weight
loss
show
reduc
viral
replic
lung
fulllength
infect
compar
sarscov
urbani
fig
e
togeth
result
establish
viabil
fulllength
suggest
adapt
requir
replic
equival
epidem
sarscov
human
respiratori
cell
mice
sarscov
epidem
link
quickli
establish
palm
civet
cov
strain
detect
human
build
find
common
emerg
paradigm
argu
epidem
sarscov
origin
bat
viru
jump
civet
incorpor
chang
within
receptorbind
domain
rbd
improv
bind
civet
ref
subsequ
exposur
peopl
liveanim
market
permit
human
infect
civet
strain
turn
adapt
becom
epidem
strain
fig
howev
phylogenet
analysi
suggest
earli
human
sar
strain
appear
close
relat
bat
strain
civet
strain
therefor
second
paradigm
argu
direct
bathuman
transmiss
initi
sarscov
emerg
palm
civet
serv
secondari
host
reservoir
continu
infect
fig
paradigm
spike
adapt
secondari
host
seen
necess
mutat
expect
occur
within
rbd
therebi
facilit
improv
infect
theori
impli
pool
bat
cov
limit
hostrang
mutat
npg
random
rare
reduc
likelihood
futur
emerg
event
human
although
studi
invalid
emerg
rout
argu
third
paradigm
circul
bat
cov
pool
maintain
pois
spike
protein
capabl
infect
human
without
mutat
adapt
fig
hypothesi
illustr
abil
chimer
viru
contain
spike
sarscov
backbon
caus
robust
infect
human
airway
cultur
mice
without
rbd
adapt
coupl
observ
previous
identifi
pathogen
cov
backbon
result
suggest
start
materi
requir
sarslik
emerg
strain
current
circul
anim
reservoir
notabl
although
fulllength
probabl
requir
addit
backbon
adapt
mediat
human
diseas
document
highfrequ
recombin
event
cov
famili
underscor
possibl
futur
emerg
need
prepar
date
genom
screen
anim
popul
primarili
use
identifi
novel
virus
outbreak
set
approach
extend
data
set
examin
question
viral
emerg
therapeut
efficaci
consid
virus
spike
potenti
threat
owe
abil
replic
primari
human
airway
cultur
best
avail
model
human
diseas
addit
observ
pathogenesi
mice
indic
capac
virus
caus
diseas
mammalian
model
without
rbd
adapt
notabl
differenti
tropism
lung
compar
attenu
fulllength
hae
cultur
rel
sarscov
urbani
suggest
factor
beyond
bindinginclud
spike
process
receptor
bioavail
antagon
host
immun
responsesmay
contribut
emerg
howev
test
nonhuman
primat
requir
translat
find
pathogen
potenti
human
importantli
failur
avail
therapeut
defin
critic
need
studi
develop
treatment
knowledg
surveil
program
diagnost
reagent
effect
treatment
produc
protect
emerg
group
cov
appli
cov
branch
maintain
similarli
heterogen
pool
addit
offer
prepar
futur
emerg
virus
approach
must
consid
context
us
governmentmand
paus
gainoffunct
gof
studi
basi
previou
model
emerg
fig
b
creation
chimer
virus
expect
increas
pathogen
although
attenu
rel
parent
mouseadapt
sarscov
similar
studi
examin
pathogen
cov
wildtyp
urbani
spike
within
backbon
show
weight
loss
mice
reduc
viral
replic
thu
rel
urbani
cov
show
gain
pathogenesi
fig
basi
find
scientif
review
panel
may
deem
similar
studi
build
chimer
virus
base
circul
strain
riski
pursu
increas
pathogen
mammalian
model
exclud
coupl
restrict
mouseadapt
strain
develop
monoclon
antibodi
use
escap
mutant
research
cov
emerg
therapeut
efficaci
may
sever
limit
move
forward
togeth
data
restrict
repres
crossroad
gof
research
concern
potenti
prepar
mitig
futur
outbreak
must
weigh
risk
creat
danger
pathogen
develop
polici
move
forward
import
consid
valu
data
gener
studi
whether
type
chimer
viru
studi
warrant
investig
versu
inher
risk
involv
overal
approach
use
metagenom
data
identifi
potenti
threat
pose
circul
bat
sarslik
cov
abil
chimer
virus
replic
human
airway
cultur
caus
pathogenesi
vivo
escap
current
therapeut
need
surveil
improv
therapeut
circul
sarslik
virus
approach
also
unlock
use
metagenom
data
predict
viral
emerg
appli
knowledg
prepar
treat
futur
emerg
viru
infect
method
associ
refer
avail
onlin
version
paper
wildtyp
sarscov
urbani
mouseadapt
sarscov
chimer
sarslik
cov
cultur
vero
cell
obtain
unit
state
armi
medic
research
institut
infecti
diseas
grown
dulbecco
modifi
eagl
medium
dmem
gibco
ca
fetal
clone
serum
fc
hyclon
south
logan
ut
along
antibioticantimycot
gibco
carlsbad
ca
dbt
cell
baric
laboratori
sourc
unknown
express
ortholog
previous
describ
human
civet
bat
sequenc
base
rhinolophu
leschenaulti
dbt
cell
express
bat
establish
describ
previous
pseudotyp
experi
similar
use
hivbas
pseudoviru
prepar
previous
describ
examin
hela
cell
wuhan
institut
virolog
express
ortholog
hela
cell
grown
minim
essenti
medium
mem
gibco
ca
supplement
fc
gibco
ca
previous
describ
growth
curv
vero
dbt
primari
human
airway
epitheli
cell
perform
previous
describ
none
work
cell
line
stock
authent
test
mycoplasma
recent
although
origin
seed
stock
use
creat
work
stock
free
contamin
human
lung
hae
cultur
procur
univers
north
carolina
chapel
hill
institut
review
boardapprov
protocol
hae
cultur
repres
highli
differenti
human
airway
epithelium
contain
ciliat
noncili
epitheli
cell
well
goblet
cell
cultur
also
grown
airliquid
interfac
sever
week
use
previous
describ
briefli
cell
wash
pb
inocul
viru
mockdilut
pb
min
inocul
cell
wash
three
time
fresh
medium
ad
signifi
time
three
biolog
replic
harvest
describ
time
point
blind
use
sampl
collect
sampl
random
viru
cultiv
perform
biosafeti
level
bsl
laboratori
redund
fan
biosafeti
cabinet
describ
previous
group
personnel
wore
power
air
purifi
respir
breath
easi
tyvek
suit
apron
booti
doubleglov
sequenc
cluster
structur
model
fulllength
genom
sequenc
amino
acid
sequenc
domain
spike
repres
cov
download
genbank
pathosystem
resourc
integr
center
patric
align
clustalx
phylogenet
compar
use
maximum
likelihood
estim
use
bootstrap
use
phyml
http
codegooglecompphyml
packag
respect
tree
gener
use
maximum
likelihood
phyml
packag
scale
bar
repres
nucleotid
substitut
node
bootstrap
support
label
tree
show
cov
divid
three
distinct
phylogenet
group
defin
classic
subgroup
cluster
mark
structur
model
gener
use
model
max
planck
institut
bioinformat
toolkit
gener
homolog
model
sar
rbd
complex
base
crystal
structur
protein
data
bank
homolog
model
visual
manipul
macpymol
version
wildtyp
chimer
virus
deriv
either
sarscov
urbani
correspond
mouseadapt
sarscov
infecti
clone
ic
previous
describ
plasmid
contain
spike
sequenc
extract
restrict
digest
ligat
e
f
plasmid
infecti
clone
clone
design
purchas
bio
basic
six
contigu
cdna
use
publish
sequenc
flank
uniqu
class
ii
restrict
endonucleas
site
bgli
thereaft
plasmid
contain
wildtyp
chimer
sarscov
genom
fragment
amplifi
excis
ligat
purifi
vitro
transcript
reaction
preform
synthes
fulllength
genom
rna
transfect
vero
cell
previous
describ
medium
transfect
cell
harvest
serv
seed
stock
subsequ
experi
chimer
fulllength
virus
confirm
sequenc
analysi
use
studi
synthet
construct
chimer
mutant
fulllength
approv
univers
north
carolina
institut
biosafeti
committe
dual
use
research
concern
committe
studi
carri
accord
recommend
care
use
anim
offic
laboratori
anim
welfar
olaw
nih
institut
anim
care
use
committe
iacuc
univers
north
carolina
chapel
hill
unc
permit
number
approv
anim
studi
protocol
iacuc
use
studi
mice
vivo
infect
femal
balb
cannhsd
mice
order
harlan
laboratori
mous
infect
done
previous
describ
briefli
anim
brought
laboratori
allow
acclim
week
infect
infect
liveattenu
viru
vaccin
mice
anesthet
mixtur
ketamin
xylazin
infect
intranas
challeng
phosphatebuff
salin
pb
dilut
viru
three
four
mice
per
time
point
per
infect
group
per
dose
describ
figur
legend
individu
mice
notat
infect
includ
failur
inhal
entir
dose
bubbl
inoculum
nose
infect
mouth
may
led
exclus
mous
data
discret
research
postinfect
preestablish
exclus
inclus
criteria
defin
blind
use
anim
experi
anim
random
vaccin
young
age
mice
vaccin
footpad
inject
volum
either
doubleinactiv
sarscov
vaccin
alum
mock
pb
mice
boost
regimen
later
challeng
thereaft
group
per
protocol
anim
monitor
daili
clinic
sign
diseas
hunch
ruffl
fur
reduc
activ
durat
experi
weight
loss
monitor
daili
first
weight
monitor
continu
anim
recov
initi
start
weight
display
weight
gain
continu
mice
lost
greater
start
bodi
weight
groundf
monitor
multipl
time
per
day
long
cutoff
mice
lost
greater
start
bodi
weight
immedi
sacrif
per
protocol
mous
deem
moribund
unlik
recov
also
human
sacrif
discret
research
euthanasia
perform
use
isofluran
overdos
death
confirm
cervic
disloc
mous
studi
perform
univers
north
carolina
anim
welfar
assur
use
protocol
approv
unc
institut
anim
care
use
committe
iacuc
histolog
analysi
left
lung
remov
submerg
buffer
formalin
fisher
without
inflat
week
tissu
embed
paraffin
section
prepar
unc
lineberg
comprehens
cancer
center
histopatholog
core
facil
determin
extent
antigen
stain
section
stain
viral
antigen
use
commerci
avail
polyclon
sarscov
antinucleocapsid
antibodi
imgenex
score
blind
manner
stain
airway
parenchyma
previous
describ
imag
captur
use
olympu
microscop
olympu
camera
viru
neutral
assay
plaqu
reduct
neutral
titer
assay
perform
previous
character
antibodi
sarscov
previous
describ
briefli
neutral
antibodi
serum
serial
dilut
twofold
incub
pfu
differ
infecti
clone
sarscov
strain
h
viru
antibodi
ad
plate
vero
cellswel
multipl
replic
n
incub
cell
overlaid
ml
agaros
medium
plate
incub
stain
neutral
red
h
plaqu
count
percentag
plaqu
reduct
calcul
plaqu
antibodyno
plaqu
without
antibodi
